Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study

Journal:

The Lancet

Published:

2025-11-12

DOI:

10.1016/s0140-6736(25)02114-2

Affiliations:

13

Authors:

19

Go to article

Institutions	Authors	Share
Altimmune, United States of America (USA)	10.500000 10.500000	0.55
Fresno Clinical Research Center, United States of America (USA)	1.000000	0.05
Indiana University Indianapolis (IU Indianapolis), United States of America (USA)	1.000000	0.05
UC San Diego Health Sciences, United States of America (USA)	1.000000	0.05
Covenant Metabolic Specialists, United States of America (USA)	1.000000	0.05
California Liver Research Institute, United States of America (USA)	1.000000	0.05
Pinnacle Clinical Research, United States of America (USA)	1.000000	0.05
Summit Clinical Research, LLC, United States of America (USA)	0.500000	0.03
Clinical Research Institute of Ohio (CRIOH), United States of America (USA)	0.500000	0.03
Scripps Health, United States of America (USA)	0.500000	0.03
Houston Methodist Hospital, United States of America (USA)	0.500000	0.03
Houston Research Institute, United States of America (USA)	0.500000	0.03

Interested in Pharmacology and Pharmaceutical Sciences?